The Australian Competition and Consumer Commission has brought legal action against Bupa alleging the aged care provider charged thousands of residents for promised extra services it did not provide.
Generic drug maker Sandoz has secured a retroactive licence to manufacture a cheaper version of top-selling antidepressant Lexapro, the drug at the heart of a long-running patent infringement battle with pharmaceutical giant Lundbeck.
A judge has denied Mylan’s bid to temporarily block Sun Pharma and Cipla from making generic versions of anti-cholesterol drug Lipidil while it appeals a ruling invalidating several claims of its patents for the drug, citing the “difficulty, complexity and uncertainty” in assessing compensation under an undertaking as to damages in pharmaceutical patent proceedings.
F. Hoffman La-Roche has reached a settlement in a patent lawsuit over Sandoz’s plan to market a biosimilar version of its patented biologic used to treat various cancers and rheumatoid arthritis.
Global pharmaceutical giant Lundbeck has launched a bid to escape a prior undertaking blocking it from appealing a court’s decision that allowed four generic drug makers to apply for licences to manufacture generic versions of popular antidepressant Lexapro.
Two generic pharmaceutical companies, Generic Partners and Apotex, have filed cross-claims alleging that Neurim Pharmaceuticals’ patent for its insomnia drug Circadin is invalid and should be revoked.
IP Australia has ordered biotech firm MacroGenics to amend its patent for a type of polypeptide used in treatments for cancer, autoimmune disorders and other diseases after a successful opposition from the chairman of intellectual property boutique Wrays.
Sirtex has been ordered to turn over information related to a possible acquisition to law firm Maurice Blackburn, which is leading a shareholder class action against the life sciences company.
A class action against Johnson & Johnson unit Ethicon over allegedly faulty pelvic mesh implants is once more vying for an expanded group definition ahead of settlement talks as the clock ticks down to judgment.
AFT Pharmaceuticals has accused rival Reckitt Benckiser of using the court as a “clearance house” to beat its competitors, the latest development in a long-running dispute over AFT’s Maxigesic ads.